Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Rintatolimod in Metastatic Pancreatic Cancer
NCT05927142Phase 2Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, rintatolimod in pancreatic ductal adenocarcinoma (PDAC). Started Jan 2024; status: active, not recruiting.
02
Drugs
durvalumabrintatolimod
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05927142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927142.